Considerations for the use of imaging tools for phase II treatment trials in oncology.
In the context of assessing tumor response, imaging tools have the potential to play a vital role in phase II and III treatment trials. If the imaging test is able to predict potential phase III success in a reliable fashion, it would be a useful tool in phase II trial design as it may provide for a more rapid and timely response assessment. The benefits and challenges of using anatomic imaging measures as well as the promising molecular imaging measures, primarily fluorodeoxyglucose-positron emission tomography, are discussed here. The general issues related to successful implementation of advanced imaging in the context of phase II treatment trials are discussed.
Shankar
Lalitha K
LK
Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA. shankarl@mail.nih.gov
Van den Abbeele
Annick
A
Yap
Jeff
J
Benjamin
Robert
R
Scheutze
Scott
S
Fitzgerald
T J
TJ
D017322:Clinical Trials, Phase II as Topic / Q000379:methods*; D023381:Endpoint Determination; D019788:Fluorodeoxyglucose F18; D046152:Gastrointestinal Stromal Tumors / Q000000981:diagnostic imaging / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D049268:Positron-Emission Tomography / Q000379:methods*; D011785:Quality Assurance, Health Care; D012509:Sarcoma / Q000000981:diagnostic imaging / Q000188:drug therapy
D019788:Fluorodeoxyglucose F18